Compare Viatris Inc (VTRS) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while YieldMax Universe Fund of Option Income ETFs trades at $7.65. The key difference: Viatris Inc pays a 2.83% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Viatris Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| VTRS | YMAX | |
|---|---|---|
Market Cap | $19.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $17.39 | $14.00 |
52-Week Low | $8.74 | $7.51 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
YMAX trades at $7.52 with no recent price movement. Technical indicators show a bearish trend with moving averages signaling sell and oscillators neutral. The stock faces significant resistance at $8 and support at $7. Recent news highlights concerns over shrinking dividends and layered fees in its fund-of-funds structure, impacting investor returns.
The outlook for YMAX is cautious due to declining dividend payouts and high fee structure risks. While oversold RSI levels may offer short-term bounce potential, fundamental data is unavailable, and sentiment is negative. Investors should weigh income erosion against technical oversold conditions before considering entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
